Brown RD - Search Results

1

Sze DM, Brown RD, Yuen E, Gibson J, Ho J, Raitakari M, Basten A, Joshua DE, Fazekas de St Groth B. Sze DM, et al. Among authors: brown rd. Leuk Lymphoma. 2003 Oct;44(10):1667-74. doi: 10.1080/1042819031000097438. Leuk Lymphoma. 2003. PMID: 14692517 Review.

2

The biology and cytogenetics of multiple myeloma.

Ho PJ, Campbell LJ, Gibson J, Brown R, Joshua D. Ho PJ, et al. Rev Clin Exp Hematol. 2002 Sep;6(3):276-300. doi: 10.1046/j.1468-0734.2002.00081.x. Rev Clin Exp Hematol. 2002. PMID: 12616699 Review.

3

B7+ T cells in myeloma: an acquired marker of prior chronic antigen presentation.

Brown R, Murray A, Pope B, Sze D, Gibson J, Ho PJ, Joshua D. Brown R, et al. Leuk Lymphoma. 2004 Feb;45(2):363-71. doi: 10.1080/10428190310001607142. Leuk Lymphoma. 2004. PMID: 15101725

4

The use of thalidomide in myeloma therapy as an effective anticancer drug.

Sze DM, Brown R, Yang S, Ho PJ, Gibson J, Joshua D. Sze DM, et al. Curr Cancer Drug Targets. 2006 Jun;6(4):325-31. doi: 10.2174/156800906777441762. Curr Cancer Drug Targets. 2006. PMID: 16848723 Review.

5

Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state.

Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D, Fromm P, Gibson J, Khoo L, Ho PJ, Joshua D. Favaloro J, et al. Leuk Lymphoma. 2014 May;55(5):1090-8. doi: 10.3109/10428194.2013.825905. Epub 2013 Aug 28. Leuk Lymphoma. 2014. PMID: 23865833

6

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma.

Favaloro J, Liyadipitiya T, Brown R, Yang S, Suen H, Woodland N, Nassif N, Hart D, Fromm P, Weatherburn C, Gibson J, Ho PJ, Joshua D. Favaloro J, et al. Leuk Lymphoma. 2014 Dec;55(12):2893-900. doi: 10.3109/10428194.2014.904511. Epub 2014 May 12. Leuk Lymphoma. 2014. PMID: 24625328

7

Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.

McAuliffe S, Brown R, Catalano A, Ho PJ, Nassif N, Woodland N, Hart D, Weatherburn C, Yang S, Suen H, Paul C, Joshua D, Gibson J. McAuliffe S, et al. Leuk Lymphoma. 2015;56(9):2714-6. doi: 10.3109/10428194.2014.1003061. Epub 2015 Feb 17. Leuk Lymphoma. 2015. PMID: 25651422 No abstract available.

8

The T Cell in Myeloma.

Joshua D, Suen H, Brown R, Bryant C, Ho PJ, Hart D, Gibson J. Joshua D, et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):537-542. doi: 10.1016/j.clml.2016.08.003. Epub 2016 Aug 10. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27601001 Review.

9

Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.

Pope B, Brown R, Luo XF, Gibson J, Joshua D. Pope B, et al. Leuk Lymphoma. 1997 May;25(5-6):545-54. doi: 10.3109/10428199709039043. Leuk Lymphoma. 1997. PMID: 9250826

10

Plasma cells in peripheral blood stem cell harvests from patients with multiple myeloma are predominantly polyclonal.

Pope B, Brown R, Gibson J, Joshua D. Pope B, et al. Bone Marrow Transplant. 1997 Aug;20(3):205-10. doi: 10.1038/sj.bmt.1700866. Bone Marrow Transplant. 1997. PMID: 9257888

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

973 results

Search Page